Ilya Rachman
Chief Executive Officer at IMMIX BIOPHARMA, INC.
Net worth: 2 M $ as of 2024-04-29
Profile
Ilya Rachman is the founder of Immix Biopharma, Inc., where he holds the title of Chairman & Chief Executive Officer since 2012.
He is also the founder of Nexcella, Inc., where he currently serves as the Executive Chairman.
Dr. Rachman has an MBA from the University of California, Los Angeles, and has completed graduate and doctorate degrees from the University of Illinois.
He also holds an undergraduate degree from the University of Iowa.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
IMMIX BIOPHARMA, INC.
4.28% | 2024-05-19 | 1,130,359 ( 4.28% ) | 2 M $ | 2024-04-29 |
Ilya Rachman active positions
Companies | Position | Start |
---|---|---|
IMMIX BIOPHARMA, INC. | Chief Executive Officer | 2011-12-31 |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Chairman | - |
Training of Ilya Rachman
University of Illinois | Doctorate Degree |
University of Iowa | Undergraduate Degree |
University of California, Los Angeles | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
IMMIX BIOPHARMA, INC. | Health Technology |
Private companies | 1 |
---|---|
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
- Stock Market
- Insiders
- Ilya Rachman